Eze Abosi cover art

Eze Abosi

Eze Abosi

Listen for free

View show details

About this listen

 Visionary Leadership in Life SciencesEze Abosi is a trailblazer in the life sciences industry, leveraging over 20 years of expertise in healthcare, data analytics, and consulting to reshape how clinical and genomic data are utilized to improve patient care. As the Chief Growth Officer at Holmusk, a Series B-stage medical technology company backed by Novartis, Abosi leads sales, marketing, and service functions, driving the company’s mission to redefine neuropsychiatry and neuroscience research. Under his leadership, Holmusk has become a critical player in the integration of clinical and genomic data, empowering researchers, healthcare providers, and biopharma companies to address the most complex challenges in healthcare.Psychedelics: A New Dimension in Mental HealthAbosi and Holmusk are at the cutting edge of psychedelic drug development, a burgeoning field that promises to revolutionize the treatment of mental health disorders. As the U.S. FDA and other global regulators begin to fast-track the approval of psychedelic therapies, Holmusk plays a critical role by providing enriched datasets that help biotech companies like Compass Pathways and Atai Life Sciences advance their clinical trials.Abosi highlights the transformative potential of psychedelics, such as psilocybin and MDMA, in treating mental health conditions like depression and anxiety. With a focus on data enrichment, Holmusk supports these organizations by creating high-quality evidence to showcase the efficacy and safety of psychedelic therapies. “The lack of significant side effects in psychedelics, compared to traditional treatments like benzodiazepines, makes them a game-changer for patients,” Abosi explains. Holmusk is also helping to bridge the gap between hallucinogenic properties and therapeutic benefits by supporting research into second-generation psychedelics that isolate medicinal properties while minimizing hallucinogenic effects.AI Drug Development: Accelerating Discovery with DataArtificial intelligence in drug development is one of the most exciting and challenging frontiers in healthcare, and Abosi is positioning Holmusk at its forefront. By integrating high-quality, curated clinical data with cutting-edge machine learning techniques, Holmusk enables biopharma companies to de-risk the critical early stages of drug discovery and clinical research.Abosi explains that Holmusk’s datasets are particularly valuable for AI applications that aim to characterize patient populations and identify underserved subgroups. This capability is especially relevant in central nervous system (CNS) disorders, where Holmusk’s enriched datasets allow researchers to stratify patients by symptoms and develop therapies targeted at specific subpopulations, such as acute anxiety or treatment-resistant depression.Despite the potential of AI in drug development, Abosi notes that progress has been relatively slow, often stalling at Phase 2 trials. However, Holmusk is working to change that by fostering collaborations with researchers and biotech firms to accelerate the application of AI in clinical trials and commercialization. “AI is only as good as the data it’s applied to,” Abosi says. “Our role is to ensure that the data is robust, enriched, and capable of driving breakthroughs in drug development.”Pioneering the Intersection of Physical and Mental HealthOne of Holmusk’s most groundbreaking achievements lies in its ability to link physical and mental health outcomes through data. Abosi points to collaborations with institutions like Oxford University and Stanford’s Bioinformatics Department as examples of how Holmusk is breaking down silos in healthcare.A notable study conducted in partnership with Oxford explored correlations between GLP-1 medications (commonly used for cardiometabolic conditions) and mental health outcomes. Holmusk’s enriched datasets revealed meaningful insights into how these medications not only improve physical health but also impact cognitive function and mental health disorders like anxiety and depression. “This research represents the holy grail of healthcare,” Abosi says. “By looking at the patient holistically, we can establish critical links between physical and brain health.”The Skinny on GLP-1: Redefining Drug Market AccessBeyond research and development, Abosi is driving innovation in how drugs are commercialized and accessed. Holmusk collaborates with payers, pharma companies, and healthcare providers to create robust economic stories for new therapies. This is particularly critical in CNS disorders, where traditional approaches to drug development and commercialization often fall short.For example, Holmusk helps manufacturers demonstrate the economic value of their therapies by showing how premium-priced medications can reduce overall healthcare costs. Abosi provides the example of GLP-1 medications: although more expensive than generics like Metformin, GLP-1s have been shown to ...
No reviews yet